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Cytometry (FCM). The levels of NF-kB p65,phospo-NF-kB p65(p-p65)
and NFATc1 of the VSMCs were determined by Western blot. TRAF6
was blocked by small interfering RNA(siRNA). MTT was used to
observe the cell proliferation. The cell supernatant of IL-2 and IL-6
were tested by ELISA.
RESULTS The level of CD137 was induced by TNF-a in smooth muscle
cells after stimulating 24h(40.002.83 vs 1.000.00,p<0.05). The
cells proliferated when treated with the agonist-CD137 mAb. The
mRNA level of NFATc1 was increased after stimulated by agonist-
CD137 mAb(2.070.09 vs 1.000.00, p<0.05), the protein of NFATc1
was also increased. Simultaneously, the mRNA level of TRAF6 was
also increased(1.390.16 vs 1.000.00,p<0.05) and p-p65 protein was
also increased(p<0.05). When TRAF6 was blocked by TRAF6 siR-
NA,the expression of p-p65 and NFATc1 was decreased after stimu-
lated by agonist-CD137 mAb compared with the stimulated
group(1.150.07 vs 2.070.09, p < 0.05). Pretreated the VSMCs with
PDTC(30mmol/L) after 30min,the expression of p-p65 was inhibited in
cytoplasm and nucleus,we stimulated the cells by agonist-CD137mAb
at this time,the mRNA level of NFATc1 was also suppressed(1.150.07
vs 2.070.09, p < 0.05) and the NFATc1 protein was inhibited(p <
0.05). The cell supernatant of IL-2 and IL-6 went up by agonist-CD137
mAb(0.910.1 vs 1.290.17,p<0.05;0.510.04 vs 0.610.07,p<0.05),
and decreased when NFATc1 was silenced(1.290.23 vs 1.000.00,
p<0.05;0.610.07 vs 0.500.03,p<0.05).
CONCLUSIONS These results demonstrates that CD137 can be induced
by TNF-a in VSMCs, and the CD137 may signaling affect the expression
of NFATc1 in mice VSMCs through TRAF6/NF-kB pathway.
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Intracoronary Cardiosphere-Derived Cells for Heart Regeneration After
Myocardial Infarction
Jie Qin, Yuefei Guo, Xiuzhen Chen, Xuelian Liu
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OBJECTIVES We aimed to assess safety of therapy with cardiosphere-
derived cells (CDCs) in patients with left ventricular dysfunction after
myocardial infarction.
METHODS An independent data coordinating center randomly allo-
cated patients in a 2:1 ratio to receive CDCs or standard care. For pa-
tients assigned to receive CDCs, autologous cells grown from
endomyocardial biopsy specimens were infused into the infarct-
related artery 1$5-3 months after myocardial infarction. The primary
endpoint was proportion of patients at 6 months who died due to
ventricular tachycardia, ventricular ﬁbrillation, or sudden unexpected
death, or had myocardial infarction after cell infusion, new cardiac
tumor formation on MRI, or a major adverse cardiac event. We also
assessed preliminary efﬁcacy endpoints on MRI by 6 months.
RESULTS Between May 1, 2009, and Dec 30, 2014, we randomly
allocated 31 eligible participants of whom 25 were included in a per-
protocol analysis. Mean baseline left ventricular ejection fraction
(LVEF) was 39% (SD 12) and scar occupied 24% (10) of left ventricular
mass. Biopsy samples yielded prescribed cell doses within 36 days (SD
6). No complications were reported within 24 h of CDC infusion. By 6
months, no patients had died, developed cardiac tumors, or MACE in
either group. Four patients (24%) in the CDC group had serious
adverse events compared with one control (13%; p¼1.00). Compared
with controls at 6 months, MRI analysis of patients treated with CDCs
showed reductions in scar mass (p¼0.001), increases in viable heart
mass (p¼0.01) and regional contractility (p¼0.02), and regional sys-
tolic wall thickening (p¼0.015). However, changes in end-diastolic
volume, end-systolic volume, and LVEF did not differ between groups
by 6 months.
CONCLUSIONS Intracoronary infusion of autologous CDCs after
myocardial infarction is safe and effective, warranting the expansion
of such therapy to phase 2 study.
GW26-e1045
ITRAQ-Based Quantitative Proteomic Analysis of Heart in a Rat Model of
Exhaustive Training
Haiyan Liu, Xuebin Cao
No. 252 Hospital of PLA
OBJECTIVES To explore the presence of informative protein bio-
markers in the rat cardiac between the health group and exhausting
group, The purpose of this study is to understand the difference inprotein expression patterns between health and after exhaustive
swimming and to evaluate the protein contributions to exhaustive
training.
METHODS 20 male SD rats (male, the weight is 20020g, SPF) were
randomly divided two groups, health group and exhausting group.
The rats of exhausting group were swimming in the artiﬁcial pond, get
the swimming method result in a model of Single Bout of Exhaustive
Swimming in Rats. After exhaustive swimming the hearts were
collected immediately. We mainly adopted advanced 8-plex ITRAQ
coupled with 2D LC-MS/MS technology for proteomics.
RESULTS Analysis of proteomic data found that 122 proteins were
identiﬁed with quantitative information between the two groups, of
with the expression level of 69 proteins had signiﬁcant differences at
least, compared with the health group(ratio＞1.2 or ＜0.7, and P ＜
0.05) ,of which 50 proteins were up-regulated, 19 proteins down-
regulated.
CONCLUSIONS This study provided a global view of potential
mechanisms and potential biomarkers of heart, and demonstrated
that iTRAQ combined with 2D LC-MS/MS quantitative proteomics is a
powerful tool for biomarker discovery.
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Cardiomyocyte Hypertrophy Via AMPK/mTOR Pathway
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OBJECTIVES Cardiac hypertrophy is the pathological basis of the
development of various cardiovascular diseases and is a major inde-
pendent risk factor of cardiovascular morbidity and mortality.
Glucagon-like peptide 1 (GLP-1), an incretin peptide released from the
intestine, exerts various cardioprotective actions and is proved to
contribute in the regulation of cardiac functions. However, the role of
Exendin-4, a stable GLP-1 analogue, in the cardiac hypertrophy re-
mains unclear.
METHODS 1. Primary neonatal ventricular cardiomyocytes were
cultured to establish the model of cardiomyocyte hypertrophy
induced by phenylephrine (PE).
2. RNA isolation and quantitative real-time PCR (q-PCR) were per-
formed to evaluate the transcriptional level of hypertrophic markers
such as ANP BNP and beta-MHC.
3. Western Blotting was carried out to observe the change of the
signaling pathway proteins levels.
4. The cardiomyocyte morphological change was manifested by
Immunoﬂuorescence staining and measurement of the cell surface
area.
RESULTS Our study demonstrated that exendin-4 attenuated cardiac
hypertrophy induced by phenylephrine (PE), manifested by decreased
hypertrophic markers such as ANP, BNP, beta-MHC and cell surface.
Phosphorylated extracellular signal regulated protein kinase (phos-
pho-ERK1/2) and phosphor-p38 mitogen-activated protein kinase
(MAPK) protein levels didn’t change in the team treated by exendin-4
and PE. In addition, we discovered that exendin (9-39), a GLP-1 re-
ceptor antagonist, can remove the anti-hypertrophic effect of exen-
din-4, evidently. Moreover, we showed that the anti-hypertrophic
effect of exendin-4 was also signiﬁcantly reversed by compound C, an
AMPK inhibitor, and rapamycin, a selective blocker of mTOR.
CONCLUSIONS These results demonstrate that exendin-4 inhibit
cardiac hypertrophy induced by PE via AMPK/mTOR pathway.
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Vascular Adventitia Calciﬁcation and its Underlying Mechanism
Na Li, Wenli Cheng
China-Japan Friendship Hospital
OBJECTIVES Previous research on vascular calciﬁcation has mainly
focused on the vascular intima and media. However, we show here
that vascular calciﬁcation may also occur in the adventitia as well. The
purpose of this work is to help elucidate the pathogenic mechanisms
underlying vascular calciﬁcation.
METHODS Mice were fed high fat diets (HFD) for 48 weeks, observing
calciﬁed lesions. Also included in this study were human subjects
aged 60 years and older that had died of coronary heart disease, heart
failure or renal failure, observing calciﬁed lesions. Explant culture of
ﬁbroblasts, the primary cell type comprising the adventitia, was
